The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model
- PMID: 2328209
- PMCID: PMC1971295
- DOI: 10.1038/bjc.1990.92
The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model
Abstract
The in vivo localising and clearance properties of conjugates of the folate-degrading enzyme carboxypeptidase G2 (CPG2) with anti-human chorionic gonadotrophin (W14A) were measured in nude mice bearing CC3 choriocarcinoma xenografts. Conjugates of W14A-F (ab')2 fragment coupled to CPG2 localised in tumour as effectively as native antibody alone but showed lower uptake in other major tissues. The clearance rates of conjugates prepared with intact antibody or F (ab')2 fragment were shown to be up to five-fold faster than for native antibody and two-fold compared to F (ab')2 fragment. Molecular weight analysis of residual conjugate in the blood showed that no degradation of conjugate to its component molecules occurred during circulation. It was concluded that F (ab')2: CPG2 conjugates offered the greatest potential for targeting applications.
Similar articles
-
Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.Br J Cancer. 1990 Dec;62(6):909-14. doi: 10.1038/bjc.1990.407. Br J Cancer. 1990. PMID: 2257218 Free PMC article.
-
Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model.Br J Cancer. 1990 May;61(5):659-62. doi: 10.1038/bjc.1990.149. Br J Cancer. 1990. PMID: 2337503 Free PMC article.
-
Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.Eur J Cancer. 1991;27(11):1361-6. doi: 10.1016/0277-5379(91)90010-b. Eur J Cancer. 1991. PMID: 1835849
-
Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.Br J Cancer. 1995 Nov;72(5):1083-8. doi: 10.1038/bjc.1995.469. Br J Cancer. 1995. PMID: 7577451 Free PMC article.
-
Altered biodistribution of an antibody--enzyme conjugate modified with polyethylene glycol.Br J Cancer. 1996 Jun;73(11):1323-7. doi: 10.1038/bjc.1996.253. Br J Cancer. 1996. PMID: 8645574 Free PMC article.
Cited by
-
Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.Br J Cancer. 1990 Dec;62(6):909-14. doi: 10.1038/bjc.1990.407. Br J Cancer. 1990. PMID: 2257218 Free PMC article.
-
Glucarpidase to combat toxic levels of methotrexate in patients.Ther Clin Risk Manag. 2012;8:403-13. doi: 10.2147/TCRM.S30135. Epub 2012 Nov 22. Ther Clin Risk Manag. 2012. PMID: 23209370 Free PMC article.
-
Reduced antibody response to streptavidin through site-directed mutagenesis.Protein Sci. 2001 Mar;10(3):491-503. doi: 10.1110/ps.19901. Protein Sci. 2001. PMID: 11344318 Free PMC article.
-
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.Br J Cancer. 2003 Aug 4;89(3):437-54. doi: 10.1038/sj.bjc.6601106. Br J Cancer. 2003. PMID: 12888809 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources